|Bid||534.40 x 0|
|Ask||534.40 x 0|
|Day's Range||529.20 - 538.40|
|52 Week Range||301.00 - 545.00|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||61.77|
|Forward Dividend & Yield||2.75 (0.51%)|
|Ex-Dividend Date||Apr 30, 2020|
|1y Target Est||N/A|
Earlier this week, Reckitt Benckiser Group Plc became the first company to win the U.S. Environmental Protection Agency’s approval to market two of its Lysol disinfectant sprays as household COVID-19 killers. Reuters previously reported that Reckitt had procured a strain of the virus from an independent lab, for testing. The EPA’s approval allows Reckitt to claim that Lysol can kill the novel coronavirus, or the SARS-CoV-2, on surfaces.
Earlier this week, Reckitt Benckiser Group Plc <RB.L> became the first company to win the U.S. Environmental Protection Agency’s approval to market two of its Lysol disinfectant sprays as household COVID-19 killers. Reuters previously reported that Reckitt had procured a strain of the virus from an independent lab, for testing. The EPA’s approval allows Reckitt to claim that Lysol can kill the novel coronavirus, or the SARS-CoV-2, on surfaces.
Inovio Pharmaceuticals Inc. has yet to share results from the Phase 1 trial for its COVID-19 vaccine candidate, but has already received millions of dollars in funding to scale up manufacturing capacity.
Lonza Group Ag (LZAGY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
The novel coronavirus pandemic has swept away several industries but has been a bit of a blessing for the biotech sector. iBio (NYSEMKT:IBIO) is one company that is benefiting from the hype surrounding the push for a vaccine, as iBio stock gained 490% this year.Source: Shutterstock As I discussed in my previous article, iBio's propriety technology called "Fast Pharming" provides the company with a unique edge in the scalability of a potential vaccine. The plant-based production system helped iBio attract investments from a few institutional investors. However, several investors are currently in two minds about investing in a vaccine inventor or a manufacturer such as iBio.This factor, along with its weak balance sheet, top the primary concerns for iBio at this time. Let's look into these aspects in more detail.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Impact of Fast Pharming I talked about Fast Pharming in-length in my previous article on iBio, however, it's best to go over it again to set up a strong premise.iBio's system combines vertical farming, automated hydroponics and glycan engineering technologies to scale up vaccines, antibodies, and other proteins. This streamlines the manufacturing system with greater consistency and efficiency. It's much quicker to grow more plants to scale up production and relatively inexpensive at the same time. * 10 Consumer Stocks to Buy to Ride the Post-Covid-19 WaveThe production system is currently a novelty in the industry. Also, it represents a significant competitive advantage for iBio to scale up production for the companies involved in creating a Covid-19 vaccine.The company is collaborating with several institutions, including the Beijing CC-Pharming, Infectious Disease Research Institute. However, iBio has not won a contract with a significant vaccine developer.Recently, Moderna (NASDAQ:MRNA) announced a partnership with Swiss company Lonza (OTCMKTS:LZAGY) to scale up production of its Covid-19 vaccine using a new mRNA technology. That makes it imperative for iBio to make some consequential moves now before it loses out on significant contracts. Financial ComparisonSource: Muslim Farooque One of the most impressive things about iBio has been its ability to gain a unique position in an industry with significant barriers to entry.From the table above, we can see that iBio has the lowest market cap compared to the three bigwigs in the biotech sector. Naturally, it has the lowest fixed and current assets in the group. In addition, its free cash flows and margins have been in the negative along with the rest of the industry.Meanwhile, iBio has done significantly better than its peers concerning revenue growth.The real figure to consider at this stage is the research and development expenditure for the four companies along with their internal resources. It is clear that iBio is at a significant disadvantage in this comparison. The company needs to consistently seek ways to pump in more cash. Look Ahead for IBIO StockDevelopers of the Covid-19 vaccine seem to be closing in on the trial phase. Global pharmaceutical giant Pfizer believes that the vaccine should be ready by October. However, that is the best-case scenario, and several experts believe that it could potentially take longer.Nevertheless, vaccine developers are now looking to form partnerships with biotech companies to scale the production of their vaccine candidates.I talked about how Moderna partnered with a Swiss biotech firm called Lonza to scale up production. Similarly, other biotech companies such as the German Vibalogics GmbH and the American Emergent BioSolutions (NYSE:EBS) recently made waves.iBio also made inroads recently. However, as we get closer to the final stages of the vaccine's development, iBio and other biotech companies will be looking to land contracts with the major vaccine developers.The companies with the most success are likely to attract the most attention from investors. iBio's Fast Pharming system could potentially play a huge role in its success going forward. The company estimates an impressive 500 million dose capacity for its Covid 19 vaccine. Bottom Line on iBio Stock iBio is in a robust position as we get closer to a Covid 19 vaccine. Its Fast Pharming system provides it a unique stability technology that could set it apart. It is time for the company to score big with some major vaccine developers as we get closer to the October window.You could play the waiting game to see which manufacturers are making the most waves in the upcoming weeks, but I believe that iBio has excellent potential. And, now is a great time to grab the stock at a discount.As of this writing, Muslim Farooque did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post iBio Is in a Healthy Position With Covid-19 Vaccine Push appeared first on InvestorPlace.
The biotech startup Moderna says it will begin the pivotal trial of its candidate vaccine against Covid-19 in July. Researchers will then watch to see how many in each group contract Covid as they go about their lives over the subsequent year. Shares of Moderna (ticker: MRNA) have soared and stooped on gusts of hope for a vaccine to end the Covid pandemic.
The current head of global pharma technical operations at Roche (OTC: RHHBY) is jumping ship to take the lead role at Lonza (OTC: LZAGY). Pierre-Alain Ruffieux will become the new chief executive officer of the contract development and manufacturing organization on Nov. 1. Ruffieux has the extensive biopharmaceutical experience that Lonza's board of directors was looking for.
Lonza Group on Friday named a veteran Roche manager to become its new chief executive, as the Swiss contract drug manufacturer seeks to end a year of turmoil at the top and accelerates work to produce a possible COVID-19 vaccine. Pierre-Alain Ruffieux, currently head of global pharma technical operations at drugmaker Roche, will join on Nov. 1, Lonza said in a statement. Before that, Ruffieux spent 12 years at Novartis, and the 50-year-old has more than 20 years of experience in the biopharmaceuticals industry.
Lonza aims to speed completion of two commercial production lines for Moderna Inc's trial COVID-19 vaccine so manufacturing could start four to six weeks earlier than planned if the project is successful, the Swiss drugmaker's chairman said on Tuesday. Lonza, which hopes to make smaller batches of active ingredients for the U.S. biotechnology company's experimental vaccine by July, now aims to finish a commercial production line in Portsmouth, New Hampshire, a month or so earlier than its original December 2020 target, Albert Baehny told Reuters. A second commercial line, at Lonza's site in Visp, Switzerland, had been slated for completion in January or February 2021 but now could be ready in December, he added.
Wildlife advocates are pushing drugmakers to curb the use of horseshoe crab blood by switching to a synthetic alternative for safety tests, including those needed before a COVID-19 vaccine can be used on humans. Fishermen net hundreds of thousands of the creatures off the U.S. East Coast and Asia every year, draining their prized milky-blue blood for use in medical safety tests that detect bacterial contamination in intravenous drugs or implants. The National Audubon Society, Defenders of Wildlife and other groups called for greater use of a man-made option, called recombinant Factor C (rFC), in a statement released on Monday by umbrella organization the Horseshoe Crab Recovery Coalition.
Horseshoe crabs' icy-blue blood will remain the drug industry's standard for safety tests after a powerful U.S. group ditched a plan to give equal status to a synthetic substitute pushed by Swiss biotech Lonza and animal welfare groups. The crabs' copper-rich blood clots in the presence of bacterial endotoxins and has long been used in tests to detect contamination in shots and infusions. More recently, man-made versions called recombinant Factor C (rFC) from Basel-based Lonza and others have emerged.
Many countries are cautiously emerging from lockdown but life may not completely return to normal until a coronavirus vaccine is found.
All eyes were on Moderna, which sparked a big rally on Wall Street after announcing promising early trial data of a coronavirus vaccine that is the furthest along among U.S. biotechs in the race.
Shares of Lonza Group climbed 2.9% in Swiss trade after Moderna reported positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus. The companies intend to manufacture the first batches of mRNA-1273 at Lonza U.S. in July 2020. Lonza shares have climbed 31% this year.
Pfizer did not specify which companies within its network it is in active discussions with about shifting production. "They have been hugely helpful in the past and will help us through this," McDermott said.
The number of patients that have recovered from the coronavirus that causes COVID-19 rose to more than a million on Friday, offering a rare piece of good news in the pandemic that has caused more than 230,000 deaths and tanked economies around the world.
Biotech Moderna (NASDAQ: MRNA) announced an agreement with Swiss drugmaker Lonza Group (OTC: LZAGY) to manufacture up to a billion doses per year of mRNA-1273, Moderna's vaccine candidate for the novel coronavirus. The two companies initially plan to establish manufacturing capabilities at Lonza's facilities in the U.S. and Switzerland to make the vaccine at both locations, with additional production suites to be established across Lonza's worldwide facilities under the 10-year agreement. The companies expect to produce the first batches of mRNA-1273 at Lonza's U.S. facility in July 2020.
Moderna and Lonza, the Swiss biotechnology company, aim to make up to 1 billion doses a year of a vaccine to combat the coronavirus.
Moderna Inc's (NASDAQ: MRNA) novel coronavirus vaccine program is brimming with activity, and the latest news out of the stable Friday is a 10-year strategic collaboration deal with Lonza, a Swiss contract development and manufacturing organization. The collaboration would help scale manufacturing of mRNA-1273, a vaccine candidate targeting SARS-CoV-2. The tie-up also covers additional Moderna products in the future.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Moderna, Lonza's Deal Terms The collaboration envisages setting up manufacturing suites at Lonza's facilities in the U.S. and Switzerland to manufacture mRNA-1273.Moderna expects the technology transfer to start in June, with the first batches of the vaccine likely to be manufactured at Lonza U.S. in July.Moderna said the companies will subsequently establish production suites across Lonza's worldwide facilities that could facilitate manufacturing material equivalent of up to 1 billion doses of the vaccine per year, assuming the individual dose is 50 micrograms.Funding for manufacturing at Lonza U.S. is partly covered by Moderna's contract with the BARDA, Moderna said."This long-term strategic collaboration agreement will enable Moderna to accelerate, by 10-times, our manufacturing capacity for mRNA-1273 and additional products in Moderna's large clinical portfolio," Moderna CEO Stephane Bancel said in a statement. Earlier this week, Moderna announced the filing of an IND application for a Phase 2 study, which is expected to commence in the second quarter contingent on favorable safety data from the NIAID-led Phase 1 study that is underway now. Recently, Emergent Biosolutions Inc (NYSE: EBS) signed an agreement with Johnson & Johnson (NYSE: JNJ) to provide CDMO services for the latter's lead COVID-19 vaccine candidate, with the deal valued at $135 million.Moderna shares were rising 6.22% to $48.85 in Friday's premarket session.Related Links:The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio See more from Benzinga * The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO * The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shares of Moderna Inc. gained 2.4% in premarket trading on Friday after the company announced a 10-year manufacturing deal with Lonza Group AG for its COVID-19 vaccine as well as its other vaccine candidates. The companies plan to set up manufacturing facilities in Switzerland, where Lonza is based, and the U.S., where they plan to make the first batch of the investigational vaccine by July. "The current pandemic illustrates the need to combine the best science with resilient supply chains that can scale," Lonza chairman Albert Baehny said in a statement. Moderna has conducted the Phase 1 trial of its COVID-19 vaccine; a Phase 2 study is expected to begin in the second quarter. There are no proven vaccines that prevent infections of the novel coronavirus. Year-to-date, Moderna's stock has soared 135.1%, while shares of Lonza have gained 19.8%. The S&P 500 is down 9.8%.
The experimental vaccine, mRNA-1273, is being tested in early-stage trial by the U.S. National Institutes of Health, with Moderna expecting to begin mid-stage trial in the second quarter. "Over time, the parties intend to establish additional production suites across Lonza's worldwide facilities, ultimately allowing for the manufacture of material equivalent to up to 1 billion doses of mRNA-1273 per year for use worldwide", the statement added. Earlier this month, Moderna got a $483 million funding from a U.S. government agency to accelerate its COVID-19 vaccine development.
Moody's Investors Service, ("Moody's") downgraded Innovative Water Care Global Corporation's (dba Sigura) Corporate Family Rating (CFR) to Caa1 from B3 and Probability of Default Rating (PDR) to Caa1-PD from B3-PD. Moody's also downgraded the first lien senior secured term loan to Caa1 from B3 and the second lien senior secured term loan to Caa3 from Caa2.
Europe should maintain a close relationship with China and avoid involvement in the ongoing U.S.-China trade war, said Merkel in an interview with the Financial Times. Germany and Europe should definitely “ensure that trade relations are fair," but at the same time should not “dismantle all interconnected global supply chains,” said Merkel. “In my opinion, complete isolation from China cannot be the answer,” she added.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Oct. 16.) Achillion Pharmaceuticals, Inc. (NASDAQ: ...